TNGX Earnings & Financial Statements
Tango Therapeutics, Inc.
$22.70
+$0.51(+2.30%)
53
Overall
45
Value
50
Tech
65
Quality
Market Cap
$3.74B
Volume
2.90M
52W Range
$6.69 - $34.39
Target Price
$43.42
TNGX earnings and financial statements: Tango Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
TNGX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $62.38M | $42.07M | $36.53M | $24.86M | $37.04M |
| Operating income | -$111.29M | -$145.59M | -$114.17M | -$111.07M | -$58.19M |
| EBITDA | -$100.96M | -$131.74M | -$102.22M | -$105.56M | -$57.29M |
| Net income | -$101.59M | -$130.30M | -$101.74M | -$108.18M | -$58.23M |
| EPS (diluted) | $-0.87 | $-1.19 | $-1.08 | $-1.23 | $-0.94 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $398.69M | $316.49M | $402.57M | $436.47M | $500.15M |
| Total liabilities | $52.51M | $116.97M | $149.46M | $186.99M | $155.41M |
| Shareholders’ equity | $346.18M | $199.52M | $253.11M | $249.48M | $344.75M |
| Cash and equivalents | $112.28M | $69.53M | $66.39M | $59.97M | $142.75M |
| Long-term debt | $30.83M | $34.04M | $36.84M | $39.36M | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$138.89M | -$131.50M | -$117.98M | -$109.08M | -$59.53M |
| Capital expenditure | -$1.05M | -$754.0K | -$1.53M | -$7.69M | -$1.84M |
| Free cash flow | -$139.93M | -$132.25M | -$119.51M | -$116.77M | -$61.36M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TNGX | $22.70 | +2.3% | 2.90M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Tango Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW